US equities
|
SPCX
$166.68
▲+4.86%
NVDA
$236.74
▲+1.19%
MU
$1,062.99
▼-1.11%
TSLA
$376.82
▲+1.68%
MSFT
$524.32
▲+1.31%
SNDK
$1,704.80
▼-0.88%
INTC
$117.36
▼-1.65%
META
$742.35
▲+1.96%
SPCX
$166.68
▲+4.86%
NVDA
$236.74
▲+1.19%
MU
$1,062.99
▼-1.11%
TSLA
$376.82
▲+1.68%
MSFT
$524.32
▲+1.31%
SNDK
$1,704.80
▼-0.88%
INTC
$117.36
▼-1.65%
META
$742.35
▲+1.96%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Femasys Inc. - Common Stock
(NQ:
FEMY
)
2.120
+0.070 (+3.41%)
Delayed Quote
Updated: 12:17 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Femasys Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care
September 15, 2026
From
Femasys Inc.
Via
GlobeNewswire
Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio
September 09, 2026
Collaboration provides dedicated patient financing for Femasys fertility solutions, helping reduce financial barriers to care across OB/GYN practices and fertility centers
From
Femasys Inc.
Via
GlobeNewswire
Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations
August 26, 2026
From
Femasys Inc.
Via
GlobeNewswire
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
August 19, 2026
Via
Chartmill
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®
August 19, 2026
-- Modular PMA pathway advances FemBloc toward potential U.S. approval while Femasys builds commercial infrastructure across its reproductive health portfolio --
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update
August 14, 2026
From
Femasys Inc.
Via
GlobeNewswire
Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents
August 12, 2026
From
Femasys Inc.
Via
GlobeNewswire
Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million
August 07, 2026
From
Femasys Inc.
Via
GlobeNewswire
Femasys Regains Compliance with Nasdaq Listing Requirements
June 24, 2026
From
Femasys Inc.
Via
GlobeNewswire
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More
↗
May 29, 2026
Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements in the global healthcare market.
Via
The Motley Fool
Topics
Regulatory Compliance
Wondering what's happening in today's after-hours session?
↗
May 25, 2026
Via
Chartmill
Get insights into the top gainers and losers of Friday's after-hours session.
↗
May 22, 2026
Via
Chartmill
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
May 13, 2026
-- New catheter complements FemVue® and supports streamlined in-office fertility evaluation --
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
May 08, 2026
-- With fertility rates at historic lows, Femasys advances access to early infertility care through FemaSeed® Complete, enabling OB/GYNs to treat patients within their own practices --
From
Femasys Inc.
Via
GlobeNewswire
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
May 05, 2026
From
Femasys Inc.
Via
GlobeNewswire
Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026
April 22, 2026
Expanding commercialization of first-line fertility treatment in the OB/GYN office to increase patient access
From
Femasys Inc.
Via
GlobeNewswire
Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio
April 16, 2026
From
Femasys Inc.
Via
GlobeNewswire
Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth
April 01, 2026
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update
March 31, 2026
-- Enrollment underway in FDA-authorized FINALE pivotal trial demonstrating execution toward FemBloc® U.S. approval --
From
Femasys Inc.
Via
GlobeNewswire
Traders are paying attention to the gapping stocks in Monday's session.
↗
March 30, 2026
Via
Chartmill
Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors
March 18, 2026
From
Femasys Inc.
Via
GlobeNewswire
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment
March 10, 2026
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access
February 26, 2026
From
Femasys Inc.
Via
GlobeNewswire
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination
February 23, 2026
From
Femasys Inc.
Via
GlobeNewswire
Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products
February 03, 2026
-- Multi-Product Distribution Agreement Marks Continued Commercial Momentum in Europe --
From
Femasys Inc.
Via
GlobeNewswire
Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
January 14, 2026
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care
January 13, 2026
Partnership enables broader adoption of FemaSeed through a trusted community health provider serving a large, engaged patient population
From
Femasys Inc.
Via
GlobeNewswire
Traders are paying attention to the gapping stocks in Monday's session.
↗
December 29, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.
Via
Chartmill
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device
December 18, 2025
From
Femasys Inc.
Via
GlobeNewswire
Wondering what's happening in today's after-hours session?
↗
December 17, 2025
As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
